<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-117351</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Epidemiology of acromegaly in Spain</dc:title>
<dc:description xml:lang="en">Epidemiology of acromegaly in Spain does not differ from that reported in other published series. Prevalence rate is approximately 60 cases per million, peak incidence occurs in middle age, more women are affected (61%), and there is a substantial delay between occurrence of the &amp;#64257;rst symptoms and diagnosis. Studies REA (Spanish Acromegaly Registry) and OASIS analyzed the epidemiology, clinical characteristics, and management of the disease in Spain. Surgery, performed in more than 80% of patients, has been (and continues to be) the main treatment for the past four decades. In the past decade, however, more patients have received somatostatin analogs (SSAs) as &amp;#64257;rst-line treatment. Use of radiation therapy has signi&amp;#64257;cantly decreased in recent decades. Somatostatin analogs (SSAs) are the most commonly used drugs, administered to 85% of patients; however, only 12%-15% continue on drug treatment alone. The surgical remission rate was 38.4% in the last decade, with a signi&amp;#64257;cant improvement overdecades. Preoperative treatment with SSAs has no in&amp;#64258;uence on surgical cure rates. Second-linet herapies used after surgical failure in the past decade included SSAs in 49% of patients, repeatsurgery in 27%, radiotherapy in 11%, pegvisomant in 15%, and dopamine agonists in 5%. Mean cost of acromegaly treatment was 9.668D (data estimated in 2009 and adjusted in 2010), of which71% was due to the cost of SSAs. Patients treated with pegvisomant have a more aggressive form of the disease and higher comorbidity rates (AU)</dc:description>
<dc:creator>Sesmilo, Gemma</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La epidemiología de la acromegalia en España no di&amp;#64257;ere de la de otras series publicadas . La prevalencia es de alrededor de 60 casos por millón, el máximo de diagnósticos ocurre en la edad media de la vida, hay predominio de mujeres (61%) y se objetiva un gran retraso entre la aparición de los primeros síntomas y el diagnóstico. Los estudios del registro español  de acromegalia (REA) y OASIS han analizado la epidemiología, las características clínicas y el tratamiento de la acromegalia en España. El tratamiento principal ha sido y sigue siendo la (..) (AU)</dc:description>
<dc:source>Endocrinol Nutr;60(8): 470-474, oct. 2013. ilus</dc:source>
<dc:identifier>ibc-117351</dc:identifier>
<dc:title xml:lang="es">Epidemiología de la acromegalia en España</dc:title>
<dc:subject>^d33003^s22006</dc:subject>
<dc:subject>^d178^s22080</dc:subject>
<dc:subject>^d22676^s32387</dc:subject>
<dc:subject>^d^s22083</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d33003^s22063</dc:subject>
<dc:type>article</dc:type>
<dc:date>201310</dc:date>
</metadata>
</record>
</ibecs-document>
